Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Finished Goods (2020 - 2025)

IGC Pharma (IGC) has disclosed Finished Goods for 6 consecutive years, with $212000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods fell 47.52% to $212000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $212000.0, a 47.52% decrease, with the full-year FY2025 number at $256000.0, down 41.95% from a year prior.
  • Finished Goods was $212000.0 for Q3 2025 at IGC Pharma, down from $271000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.0 million in Q3 2021 to a low of $212000.0 in Q3 2025.
  • A 5-year average of $591631.6 and a median of $533000.0 in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 222.95% in 2021, then tumbled 47.52% in 2025.
  • IGC Pharma's Finished Goods stood at $889000.0 in 2021, then decreased by 20.58% to $706000.0 in 2022, then decreased by 27.62% to $511000.0 in 2023, then dropped by 28.77% to $364000.0 in 2024, then tumbled by 41.76% to $212000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Finished Goods are $212000.0 (Q3 2025), $271000.0 (Q2 2025), and $256000.0 (Q1 2025).